Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir for COVID-19 ARDS in ICU patients
IRCT20150107020592N26Phase 3Completed
- Sponsor
- Masih Daneshvari Hospital
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of favipiravir in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS), sponsored by Masih Daneshvari Hospital. Primary endpoints: Oxygenation and Chest X-ray. Started Mar 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20150107020592N26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150107020592N26.